Flecainide dose-response relations in stable ventricular arrhythmias.
Flecainide dose-response relations in stable ventricular arrhythmias.
复制标题
稳定室性心律失常中氟卡尼的剂量反应关系。
DOI：
10.1016/0002-9149(84)90504-6
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
Roden,DM
中科院分区：
文献类型：
--
作者：
Woosley,RL;Siddoway,LA;Duff,HJ;Roden,DM
在一项安慰剂对照、剂量范围探索研究中对醋酸氟卡尼进行了评价，该研究在稳定的高频室性心律失常患者中进行。三个中心研究了35名患者的3阶段方案。在安慰剂基线后，评价口服剂量从100 mg增加至300 mg每日两次。然后重新开始安慰剂治疗，心律失常复发后，患者出院，接受有效剂量治疗，7天和14天后返回诊所进行评估。35例患者中有30例室性早搏（VPC）抑制率超过80%（平均96%），复杂VPC减少率超过95%。在73%的患者中，在100至200 mg每日两次的剂量下观察到心律失常抑制。23%的患者需要500至600 mg/天。46%的患者出现轻度副作用。在大多数患者中，这些在较低剂量下消退或变得可耐受。29例患者中有24例持续有效治疗2年，无任何慢性毒性证据。药代动力学研究表明，许多患者在达到稳态之前需要5至7天的恒定给药。醋酸氟卡尼是一种有效的抗心律失常药物，有效剂量范围较窄。
Flecainide acetate was evaluated in a placebo-controlled, dose-ranging study performed in patients with stable, high-frequency ventricular arrhythmias. Three centers studied 35 patients in a 3-stage protocol. After a placebo baseline, increasing oral dosages from 100 to 300 mg twice daily were evaluated. Placebo was then reinstituted and after arrhythmia had recurred, the patients were discharged on the effective dosage to return to the clinic for evaluation 7 and 14 days later. Thirty of 35 patients had more than 80% suppression (mean 96%) of ventricular premature complexes (VPCs) and more than 95% reduction in complex VPCs. Arrhythmia suppression was seen at dosages of 100 to 200 mg twice daily in 73% of the patients. Twenty-three percent of patients required 500 to 600 mg/day. Mild side effects were seen in 46% of patients. These resolved or became tolerable at lower dosages in most patients. Effective therapy continued for 2 years in 24 of 29 patients, without any evidence of chronic toxicity. Pharmacokinetic studies indicate that many patients require 5 to 7 days of constant dosing before reaching steady state. Flecainide acetate is an effective antiarrhythmic with a narrow range of effective dosages.